MARKET

MOLN

MOLN

MOLECULAR PARTNERS AG
NASDAQ
4.100
0.000
0.00%
Closed 09:30 05/08 EDT
OPEN
4.100
PREV CLOSE
4.100
HIGH
4.100
LOW
4.100
VOLUME
5.86K
TURNOVER
--
52 WEEK HIGH
5.36
52 WEEK LOW
3.410
MARKET CAP
165.54M
P/E (TTM)
-1.9669
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MOLN last week (0427-0501)?
Weekly Report · 6d ago
Molecular Partners presents MP0712 data at upcoming scientific conferences
PUBT · 6d ago
Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences
Barchart · 6d ago
Molecular Partners publishes MP0317 clinical data in Nature Cancer
TipRanks · 05/01 11:32
Molecular Partners Announces Publication Of Phase 1 Clinical Data In 'Nature Cancer' That Illustrate The Potential Of Tumor-Localized CD40 Agonist, MP0317, To Modulate The Tumor Microenvironment
Benzinga · 05/01 11:08
MOLECULAR PARTNERS AG - MP0317 SHOWED FAVORABLE SAFETY UP TO HIGHEST DOSE AND SUITABILITY FOR WEEKLY OR THREE-WEEK DOSING
Reuters · 05/01 11:00
MOLECULAR PARTNERS PUBLISHES PHASE 1 MP0317 DATA IN NATURE CANCER DEMONSTRATING TUMOR-LOCALIZED CD40 ACTIVATION AND TUMOR MICROENVIRONMENT REMODELING
Reuters · 05/01 11:00
Molecular Partners publishes Phase 1 MP0317 data showing tumor-localized CD40 activation
PUBT · 05/01 11:00
More
About MOLN
Molecular Partners AG is a Switzerland-based company engaged in the pharmaceuticals industry. As a biopharmaceutical company, it is active in the research and development of proteins like DARPins (Designed Ankyrin Repeat Proteins), a new class of small proteins used for the development of medicine against diseases like cancer and sight-threating diseases, among others. The Company’s pipeline is structured mainly through three areas: Ophthalmology, including the creation of therapies for renital diseases like wet age-related macular degeration (wet AMD) and diabetic macular edema (DME); Oncology, containing the development of DARPins against cancer, among others; and Immunology and other Indications, entailing DARPins against several targets important for the treatment of inflammatory and auto-immune diseases.

Webull offers Molecular Partners AG (ADR) stock information, including NASDAQ: MOLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MOLN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MOLN stock methods without spending real money on the virtual paper trading platform.